澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

MAYNE PHARMA GROUP LTD

2.960

-0.040-1.33%

成交量：23.81萬

成交額：70.62萬

市值：2.42億

市盈率：14.26

高：3.010

開：3.000

低：2.920

收：3.000

52周最高：6.500

52周最低：2.040

股本：8,189.09萬

流通股本：6,699.72萬

量比：0.57

換手率：0.36%

股息：- -

股息率：- -

每股收益(TTM):0.208

每股收益(LYR):0.208

淨資產收益率：8.20%

總資產收益率：-1.73%

市淨率：0.62

市盈率(LYR):14.26

資料載入中...

總覽公司新聞公告

概念

醫藥生物股-1.73%

資金流向

資金流入：

資金流出：

新聞

Mayne Pharma澄清：CEO未參與任何涉及自身激勵方案的薪酬決策

異動解讀 | Mayne Pharma Group盤中大漲5.58%，或因考慮股票回購計劃提振市場信心

Mayne Pharma Group持續評估資本配置策略或考慮實施市場股票回購計劃

MAYNE PHARMA GROUP LTD：南澳大利亞索爾茲伯裏生產基地預計影響甚微，因出口美國產品多為仿製藥

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/MYX.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":2.96,"timestamp":1789107120000,"preClose":3,"halted":0,"volume":238134,"delay":0,"changeRate":-0.013333333333333345,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66997185,"shares":81890887,"eps":0.207588,"marketStatus":"休市中","change":-0.04,"latestTime":"09-11 16:12:00 AEST","open":3,"high":3.01,"low":2.92,"amount":706238,"amplitude":0.03,"askPrice":3,"askSize":1876,"bidPrice":2.91,"bidSize":3400,"shortable":3,"etf":0,"ttmEps":0.207588,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":3,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.5720095928238299,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MYX.AU","preClose":3,"auctionPrice":2.96,"auctionVolume":1594,"auction":3,"marketStatus":"盘后竞价","timestamp":1789107003557}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66997185,"roa":"-1.73%","roe":"8.20%","lyrEps":0.207588,"volumeRatio":0.5720095928238299,"shares":81890887,"dividePrice":0,"high":3.01,"amplitude":0.03,"preClose":3,"low":2.92,"week52Low":2.04,"pbRate":"0.62","psRate":"0.63","week52High":6.5,"institutionHeld":0,"latestPrice":2.96,"committee":0.288855,"eps":0.207588,"divideRate":0,"volume":238134,"delay":0,"ttmEps":0.207588,"open":3,"prevYearClose":3.11,"prevWeekClose":3.11,"prevMonthClose":3.1,"prevQuarterClose":2.79,"fiveDayClose":3.11,"twentyDayClose":3.2,"sixtyDayClose":2.34,"dividendPayoutRate":0.04569711225089115,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.014818181818181815},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-22","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2025-08-29","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756425600000,"name":null,"time":"","dateTimestamp":1756389600000,"actualEps":null},{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1174993621","title":"Mayne Pharma澄清：CEO未參與任何涉及自身激勵方案的薪酬決策","url":"https://stock-news.laohu8.com/highlight/detail?id=1174993621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174993621?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 06:25","pubTimestamp":1777501505,"startTime":"0","endTime":"0","summary":"Mayne Pharma集团今日发布声明，明确表示公司首席执行官在涉及向其本人授予激励措施的薪酬决策过程中全程回避。该制药企业强调，相关薪酬决议完全由董事会下设的薪酬委员会独立制定，确保公司治理流程符合最高标准的透明性与规范性要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MYX.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161898046","title":"異動解讀 | Mayne Pharma Group盤中大漲5.58%，或因考慮股票回購計劃提振市場信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1161898046","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161898046?lang=zh_tw&edition=fundamental","pubTime":"2026-04-29 08:17","pubTimestamp":1777421842,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group Ltd（ASX: MYX）今日盘中大涨5.58%，引起了市场的广泛关注。消息面上，该公司表示正在持续评估最优资本配置方案，管理层考虑的策略选项中可能包含在公开市场回购公司股票的计划。市场分析人士指出，若实施股票回购计划，将有助于优化资本结构并提升股东价值，这提振了投资者信心。该公司强调，资本配置策略的审查工作仍在进行中，最终方案将综合考虑公司财务状况、市场环境及未来发展需求等因素。此次股价上涨反映了市场对公司潜在积极举措的乐观预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136228232","title":"Mayne Pharma Group持續評估資本配置策略 或考慮實施市場股票回購計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1136228232","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136228232?lang=zh_tw&edition=fundamental","pubTime":"2026-04-29 07:37","pubTimestamp":1777419437,"startTime":"0","endTime":"0","summary":"澳大利亚制药企业Mayne Pharma Group Ltd（ASX: MYX）近日表示，公司正在持续评估最优资本配置方案。据悉，管理层考虑的策略选项中可能包含在公开市场回购公司股票的计划。\n该公司强调，资本配置策略的审查工作仍在进行中，最终方案将综合考虑公司财务状况、市场环境及未来发展需求等因素。市场分析人士指出，若实施股票回购计划，将有助于优化资本结构并提升股东价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139649848","title":"MAYNE PHARMA GROUP LTD：南澳大利亞索爾茲伯裏生產基地預計影響甚微，因出口美國產品多為仿製藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1139649848","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139649848?lang=zh_tw&edition=fundamental","pubTime":"2026-04-07 07:46","pubTimestamp":1775519173,"startTime":"0","endTime":"0","summary":"MAYNE PHARMA GROUP LTD 位于南澳大利亚州索尔兹伯里的生产基地预计将受到极小影响。这一判断主要基于其出口至美国市场的产品结构中，仿制药占据了主导地位。此类产品通常具有稳定的市场需求和成熟的供应链体系，能够有效缓冲外部环境变化带来的潜在冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MYX.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.017262}]}}